BRAIN-DERIVED SPECIFIC MOLECULAR AND CELL-TYPE RNA MARKERS FOR DIAGNOSING AND TREATING DEPRESSION

Background

The field of psychiatric biomarker research has long sought reliable, accessible indicators of brain pathology to improve the diagnosis and management of disorders such as major depressive disorder (MDD). Traditional psychiatric diagnoses rely heavily on subjective symptom reporting and clinical interviews, which can be imprecise. Given the inaccessibility of living human brain tissue, researchers have turned to peripheral samples, such as blood, in hopes of identifying molecular signatures that mirror brain dysfunction. This rationale is supported by evidence of immune-brain communication, where peripheral immune cells can influence or reflect central nervous system processes, particularly in the context of stress and psychiatric illness. The development of blood-based biomarkers holds promise for non-invasive, dynamic monitoring of disease state, risk stratification, and treatment response in psychiatric populations. However, most blood-based biomarker studies in psychiatry have focused on protein-level markers, which often yield inconsistent results and lack specificity for particular psychiatric conditions. Furthermore, existing studies rarely integrate multi-level data—such as single-cell transcriptomics, immune cell phenotyping, and brain-blood molecular correlations—leaving gaps in our understanding of how peripheral signals relate to central pathology. As a result, there remains a critical need for more sensitive, specific, and mechanistically informed approaches to identify peripheral biomarkers that truly reflect brain dysfunction in psychiatric disorders.

Technology Description

This technology is an integrated molecular profiling platform designed to identify and characterize transcriptomic correlations between brain tissue and peripheral blood, with the goal of developing blood-based biomarkers of neuropsychiatric and neurodegenerative conditions such as major depressive disorder (MDD). The system utilizes bulk and single-nucleus RNA sequencing, spatial transcriptomics, proteomics, and epigenomics to analyze postmortem brain regions alongside peripheral blood mononuclear cells. A computational engine processes these multiomic inputs to construct a three-tiered transcription factor regulatory hierarchy: Tier 1 master regulators that establish disease-state identity, Tier 2 context regulators that modulate inflammatory and metabolic adaptation, and Tier 3 downstream effectors that execute cellular stress responses. By mapping concordant and discordant transcriptomic correlations between brain and blood the platform translates central nervous system regulatory network failures into peripheral biomarkers that correlate with clinical phenotypes, including depression severity, suicide risk, and therapeutic response.